Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

Vaccine

Volumn 16, Issue 9-10, 1998, Pages 960-968

  Kistner, O ^a   Barrett, P N ^a   Mundt, W ^a   Reiter, M ^a   Schober Bendixen, S ^a   Dorner, F ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Influenza vaccine; Serum free; Vero cell

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; DOSE RESPONSE; DRUG PURIFICATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; VACCINE PRODUCTION; VERO CELL; VIRUS INACTIVATION; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIBODIES, VIRAL; BIOTECHNOLOGY; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; CULTURE MEDIA, SERUM-FREE; IMMUNIZATION; INFLUENZA VACCINES; MICE; NEURAMINIDASE; ORTHOMYXOVIRIDAE; SAFETY; VACCINES, INACTIVATED; VERO CELLS; VIRUS CULTIVATION;

EID: 0032078697     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00301-0     Document Type: Article

References (34)

1. 1 Rowe, P.M. Pandemic influenza (un)preparedness described. The Lancet 1995, 346, 1699.
2. 2 Petricciani, J.C. Regulatory philosophy and acceptability of cells for the production of biologicals. Dev. Biol. Stand. 1991, 75, 9-15.
3. 3 Schild, G.C., Oxford, J.S., De Jong, J.C. and Webster, R.G. Evidence for host-cell selection of influenza virus antigenic variants. Nature (London) 1983, 303, 706-709.
4. 4 Robertson, J.S., Bootman, J.S. and Newman, R. et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A (H1N1) virus. Virology 1987, 160, 31-37.
5. 5 Hardy, C.T., Young, S.A., Webster, R.G., Naeve, C.W. and Owens, R.F. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of Influenza A (H3N2) virus. Virology 1995, 211, 302-306.
6. 6 Robertson, J.S. Clinical influenza virus and the embryonated hen's egg. Rev. Med. Virol. 1993, 3, 97-106.
7. 7 Katz, J.M. and Webster, R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 1989, 160, 191-198.
8. 8 Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. WHO 1995, 73, 431-435.
9. 9 Brands, R., Palache, A.M. and van Scharrenburg, G.J.M. Madin Darby Canine Kidney (MDCK)-cells for the production of inactivated influenza subunit vaccine. Safety characteristics and clinical results in the elderly. In: Options for the Control of Influenza III. Proceedings of the Third International Conference on Options for the Control of Influenza, Cairns, Australia, 4-9 May 1996 (Eds Brown, L.E., Hampson, A.W. and Webster, R.G.). Excerpta Medica. 1996, pp. 683-693.
10. 10 Palache, A.M., Brands, R. and van Scharrenburg, G.J.M. Immunogenicity and reactogenicity of influenza subunit vaccines produced either in Madin Darby Kidney (MDCK)-cells or in fertilised chicken eggs. J. Infect. Dis. 1997, 176., (suppl. 1), 20-23.
11. 11 Montagnon, B.J., Fanget, B. and Nicholas A.J. The large-scale cultivation of Vero cells in microcarrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev. Biol. Stand. 1987, 47-55.
12. 12 Nakamura, K. and Homma, M. Protein synthesis in Vero cells abortively infected with Influenza B virus. J. Gen. Virol. 1981, 56, 199-202.
13. 13 Lau, S.C. and Scholtissek, C. Abortive infection of Vero cells by an Influenza A virus (FPV). Virology 1995, 212, 225-231.
14. 14 Govorkova, E.A., Murti, G., Meignier, B., De Taisne, C. and Webster, R.G. African Green Monkey Kidney (Vero) cells provide an alternative host cell system for Influenza A and B virus. J. Virol. 1996, 70, 5519-5524.
15. 15 Wood, J.M., Schild, G.C., Newman, R.W. and Seagroatt, V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 1977, 5, 237-247.
16. 16 Aymard-Henry, M., Coleman, M.T., Dowdle, W.R., Laver, W.G., Schild, G.C. and Webster, R.G. Influenza virus neuraminidase and neuraminidase-inhibition test procedures. Bull. WHO 1973, 48, 199-202.
17. 17 Lämmli, U.K. Cleavage of structural proteins during the assembly of the head of Bacteriophage T4. Nature 1970, 227, 680-685.
18. 18 Cavalli Sforza, L. Biometrie - Grundzüge biologisch-medizinischer Statistik 3rd edition. Gustav Fischer, Stuttgart, 1972, pp. 159-186.
19. 19 Yasumura, Y. and Kawakita, Y. Studies on SV40 in tissue culture - Preliminary step for cancer research "in vitro" (translated from Nihon Rinsho 1963, 21, 1201-1215 in Japanese). In: Vero Cells - Origin, Properties and Biomedical Applications (Eds Simizu, E. and Terasima, T.). Department of Microbiology, Chiba University, Japan, 1988, pp. 1-19.
20. 20 Horaud, F. Absence of viral sequences in the WHO-Vero cell bank: a collaborative study. Develop. Biol. Stand. 1992, 76, 43-46.
21. 21 Vincent-Falquet, J.C., Peyron, L., Souvras, M., Moulin, J.C., Tektoff, J. and Patet, J. Qualification of working cell banks for the Vero cell line to produce licensed human vaccines. Dev. Biol. Stand. 1989, 70, 153-156.
22. 22 Levenbook, I.S., Petricciani, J.C. and Elisberg, B.L. Tumor-ogenicity of Vero cells. J. Biol. Stand. 1984, 12, 391-398.
23. 23 Furesz, J., Fanok, A., Contreras, G. and Becker, B. Tumor-ogenicity testing of various cell substrates for production of biologicals. Dev. Biol. Stand. 1989, 70, 233-243.
24. 24 European Pharmacopeia 3rd Edition, 1997, 0159 (1-4). Influenza Vaccine (whole virion, inactivated).
25. 25 Points to consider in the characterization of cell lines used to produce biologicals, Office of Biologics Research and Review, Centre for Drugs and Biologics, FDA (USA) 1993.
26. 26 Murphy, B.R. and Webster R.G. Orthomyxoviruses. In: Fields Virology Vol. 1, 3rd edition (Eds. Field, B.N., Knipe, D.M., Howley, P.M., Chanock, R.M., Melnick, J.L., Monath, T.P., Roizman, B. and Straus, S.E.). Lippincott-Raven, Philadelphia, 1996, pp. 1397-1446.
27. 27 Lazarowitz, S.G. and Choppin, P.W. Enhancement of the infectivity of Influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 1975, 68, 440-454.
28. 28 Rott, R., Reinacher, M., Orlich, M. and Klenk, H.-D. Cleavability of hemagglutinin determines spread of avian influenza viruses in the chorioallantoic membrane of chicken embryo. Arch. Virol. 1980, 65, 123-133.
29. 29 Klenk, H.-D., Rott, R., Orlich, M. and Blödorn, J. Activation of influenza A viruses by trypsin treatment. Virology 1975, 68, 426-439.
30. 30 Stienecke-Gröber, A., Vey, M. and Angliker, H. et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO 1992, 11, 2407-2414.
31. 31 Govorkova, E.A., Kaverin, N.V., Gubareva, L.V., Meignier, B. and Webster, R.G. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J. Infect. Dis. 1995, 172, 250-253.
32. 32 Kaverin, N.V. and Webster, R.G. Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity. J. Virol. 1995, 69, 2700-2703.
33. 33 Oxford, J.S., Corcoran, T. and Knott, R. et al. Serological studies with influenza A(H1N1) viruses cultivated in eggs or in a canine kidney cell line (MDCK). Bull. WHO 1987, 65, 181-187.
34. 34 Katz, J.M., Naeve, C.W. and Webster, R.G. Host cell-mediated variation in H3N2 influenza viruses. Virology 1987, 156, 386-395.